newsfilter
← Latest News
Business Wire·

Evommune Reports First Quarter 2026 Financial Results and Provides Business Highlights

‑ Phase 2b top-line data from EVO756 in chronic spontaneous urticaria (CSU) and atopic dermatitis (AD) on track for June 2026 and 3Q26, respectively, with enrollment complete in both trials ‑ Phase 2b clinical trial